DEFTA Partners
VC Fund
San Francisco, United States
DEFTA Partners is a venture capital firm focusing on technology. They primarily make seed and first round investments in early stage information technology companies with global opportunities to accelerate growth. DEFTA has offices and partners in the United States, Japan, Israel and the United Kingdom. via: DEFTA Partners
- Total investments:
- 32
- Last investment:
- Lead investor:
- 22%
- Fund size:
- $63M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries DEFTA Partners invests in
Stages DEFTA Partners invests in
Countries DEFTA Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $2.5M–$13M
- Series B
- $6.5M–$47M
Investment Focus
Industry
- Biotechnology 8 (25%)
- Medical 7 (22%)
- Health Care 7 (22%)
- Software 6 (19%)
- Therapeutics 5 (16%)
Stage
- Series A 12 (38%)
- Series B 5 (16%)
- Funding Round 4 (13%)
- Series D 2 (6%)
- Seed 1 (3%)
Country
- United States 16 (50%)
- Israel 2 (6%)
- Japan 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Arie Kahana
Partner
|
Partner | Total investments: 0 | Find email | |
Kyoko Watanabe
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Masa Isono
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Endogena
|
Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders.The company implements innovation in the field of regenerative medicine. Their sciencecombines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases. | $21M / Series A / Dec 13, 2021 | |
DiA Imaging Analysis
|
DiA Imaging Analysis provides advanced AI-based ultrasound analysis smarter and accessible. It solves the two main challenges clinicians face when using ultrasound: acquiring the right image and automatically analyzing it, to find clinical abnormalities that today they are struggling to find visually. DiA's automated tools can be easily beadded to any ultrasound device or healthcare IT system, just like an App.The company holds FDA/CE Clearances for its cardiac toolbox, generating revenues and having thousands of users around the world. | $14M / Venture - Series Unknown / Aug 24, 2021 | |
InformAI
|
InformAI is a technology company dedicated to advancing healthcare through AI-enabled clinical solutions. We specialize in creating sophisticated products for oncology and diagnostic imaging to improve patient outcomes. Leveraging strong partnerships, we deliver impactful solutions in large and fast growing markets. Located in the Texas MedicalCenter in Houston, Texas (largest global medical center), we have access to world renowned medical experts, medical institutions and proprietary datasets. | $1.5M / Seed / May 01, 2021 | |
Acepodia
|
Acepodia is a novel technology platform to arm immune cells with antibodies to cure cancer. The Next Generation of Immunotherapies.Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targetinga different type of cancer. | $47M / Series B / Mar 16, 2021 | |
|
Endogena
|
Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders.The company implements innovation in the field of regenerative medicine. Their sciencecombines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases. | $8M / Series A / Jan 28, 2021 | |
Aegle Therapeutics
|
Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skinblistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis.The company was founded in 2013 and is based in Miami, Florida. | $6.5M / Series A / Sep 29, 2020 | |
|
InformAI
|
InformAI is a technology company dedicated to advancing healthcare through AI-enabled clinical solutions. We specialize in creating sophisticated products for oncology and diagnostic imaging to improve patient outcomes. Leveraging strong partnerships, we deliver impactful solutions in large and fast growing markets. Located in the Texas MedicalCenter in Houston, Texas (largest global medical center), we have access to world renowned medical experts, medical institutions and proprietary datasets. | $1.8M / Seed / Jun 26, 2020 | |
TARA Biosystems
|
Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiacfunctionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines. | $10M / Series A / Jun 23, 2020 | |
1World Online
|
1World Online is a A.I.-powered platform that unifies the values of data and advertising into an all-in-one engagement driven model. With 1World Online, websites will enjoy higher metrics of engagement, business teams will be able to better understand, profile, and monetize the audience, editors and journalists gain access to timely news contentand can better target stories, and improve reader relationships.The company was founded in 2011 and is headquartered in California and Switzerland. | $8.5M / Series A / Feb 21, 2020 | |
|
Aegle Therapeutics
|
Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skinblistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis.The company was founded in 2013 and is based in Miami, Florida. | $4M / Series A / Jan 09, 2020 | |
| See all 32 investments → | |||
Co-Investors
Bios Partners
3 deals together
Hatteras Venture Partners
3 deals together
LabCorp
3 deals together
Walden Venture Capital
3 deals together
180 Degree Capital
2 deals together
Alexandria Venture Investments
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does DEFTA Partners invest in?
DEFTA Partners invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DEFTA Partners's check size?
DEFTA Partners typically joins rounds of $2.5M–$13M at Series A and $6.5M–$47M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DEFTA Partners participates in.
How do I contact DEFTA Partners?
Public channels for DEFTA Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DEFTA Partners?
The team at DEFTA Partners includes Arie Kahana (Partner), Kyoko Watanabe (Managing Director) and Masa Isono (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
